Scarica l'app Stockscreener
6.9753
1.97%
-0.1247
Purple Biotech Ltd Adr Borsa (PPBT) Ultime notizie
Ratio Review: Analyzing Purple Biotech Ltd ADR (PPBT)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire Inc.
What Makes Purple Biotech (PPBT) a New Buy Stock - Yahoo Finance
Purple Biotech stock target cut on trial cohort issue - Investing.com
Purple Biotech granted Nasdaq compliance extension - Investing.com
95 Promising Stocks You Can Currently Buy for Less Than $5 Per Share - GOBankingRates
Purple Biotech stock retains Buy rating from H.C. Wainwright - Investing.com
Purple Biotech Ltd ADR (PPBT) Stock Behavior Isn't As Predictable As You Think – Stocks Register - Stocks Register
Financial Fitness Check: Examining Purple Biotech Ltd ADR (PPBT)’s Key Ratios - The Dwinnex
You might want to take a look at Purple Biotech Ltd ADR (PPBT) now – Sete News - SETE News
Why Purple Biotech (PPBT) Shares Are Trading Lower - Quantisnow
The Significance of Moving Averages in Purple Biotech Ltd ADR Inc. (PPBT) Price Performance - The InvestChronicle
Why Purple Biotech (PPBT) Shares Are Trading Lower - TradingView
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds - GlobeNewswire Inc.
A closer look at Purple Biotech Ltd ADR (PPBT)'s stock price trends – US Post News - US Post News
Why Purple Biotech (PPBT) Shares Are Trading Lower - Benzinga
Manulife Financial Corp. [MFC] gain 19.91% so far this year. What now? – The DBT News - The DBT News
Purple Biotech Ltd ADR Inc. (PPBT) Price Performance: The Role of Volume and Liquidity - The InvestChronicle
Analyzing PPBT's price-to-book ratio for the last quarter – US Post News - US Post News
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit - GlobeNewswire Inc.
Purple Biotech Ltd ADR (PPBT) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Insider's View: Deciphering Purple Biotech Ltd ADR (PPBT)'s Financial Health Through Ratios – DWinneX - The Dwinnex
Purple Biotech shares target cut by Jones Trading on interim Ph2 data - Investing.com India
Purple Biotech shares target cut by Jones Trading on interim Ph2 data By Investing.com - Investing.com
Purple Biotech shares target cut by Jones Trading on interim Ph2 data - Investing.com
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer - GlobeNewswire Inc.
A stock that deserves closer examination: Purple Biotech Ltd ADR (PPBT) – US Post News - US Post News
Purple Biotech Ltd ADR (PPBT) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Purple Biotech Reports First Quarter 2024 Financial Results - GlobeNewswire Inc.
Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher - Yahoo Finance
7 High-Potential Penny Stocks in the Biotech Sector - InvestorPlace
A new, genetically modified purple tomato may hit the grocery market stands - CNN
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday - The Globe and Mail
The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues - Benzinga
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
Purple Biotech (PPBT) Stock Price, News & Analysis - MarketBeat
1.16%
2.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):